Explore
Trendline
CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026
CervoMed Inc. Reports Zero Revenue and Increased Net Loss in Q1 2026
Read More
Trendline
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Brainstorm Cell Therapeutics Reports Narrowed Losses in Q1 2026
Read More
Trendline
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Edesa Biotech Reports Increased Net Loss Amid R and Manufacturing Expansion
Read More
Trendline
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Inhibrx Reports First Quarter 2026 Financial Results Highlighting Clinical Progress
Read More
Trendline
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
INOVIO Reports First Quarter 2026 Financial Results Amid Regulatory Review of INO-3107
Read More
Trendline
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
NanoViricides Reports Q3 FY2026 Financial Results, Advances Clinical Trials
Read More
Trendline
Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements
Alpha Cognition Reports Q1 2026 Financial Results Highlighting Revenue Growth and Clinical Advancements
Read More
Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results
Immunome Submits NDA for Varegacestat and Reports Financial Results
Read More
Trendline
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Guided Therapeutics Reports Q1 2026 Financial Results with No Revenue
Read More
Trendline
Nanalysis Scientific Corp to Host First Quarter 2026 Conference Call for Investors
Nanalysis Scientific Corp to Host First Quarter 2026 Conference Call for Investors
Read More
Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Read More
Trendline
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Imunon, Inc. Reports Increased Net Loss in Q1 2026 Amid Clinical Advancements
Read More
